Eli Lilly & Co. (LLY)

Novo Nordisk announced a new subscription model for Wegovy offering 3, 6, or 12-month prescriptions at discounted prices to expand market reach in the weight-loss drug space. Despite losing market leadership to Eli Lilly, the company's pricing strategy could help penetrate the underpenetrated obesity market, where only 12% of Americans currently use GLP-1 drugs despite 40-70% obesity rates. Novo Nordisk stock trades at an attractive valuation of 11x forward earnings compared to healthcare average of 17.3x.

The Motley Fool•Prosper Junior Bakiny

Apr 3

Viking Therapeutics, a clinical-stage biotech company, is developing VK2735, a dual GLP-1/GIP agonist for weight management currently in phase 3 trials. The company could potentially capture significant market share in the projected $100+ billion weight-loss market if VK2735 demonstrates efficacy comparable to Eli Lilly's Zepbound. However, the company faces substantial risks including clinical setbacks, intense competition, and the historical difficulty most biotechs face in achieving sustained success.

The Motley Fool•Prosper Junior Bakiny

Apr 3

Major M&A activity dominates the market with McCormick merging with Unilever's Foods business in a $29.1 billion deal, Sysco acquiring Jetro Restaurant Depot for $29 billion, and Eli Lilly acquiring Centessa Pharmaceuticals for $7.8 billion. Meanwhile, QVC faces financial distress and is considering Chapter 11 bankruptcy, while several other companies including IO Biotech and Lipella Pharmaceuticals have filed for bankruptcy.

Benzinga•Caroline Ryan

Apr 3

U.S. stock markets opened sharply lower on April 2, 2026, amid Iran conflict concerns and Tesla's disappointing delivery report, but recovered to near breakeven by midday. Oil prices surged 10% following Trump's Wednesday address, though reports of Iran-Oman negotiations on Strait of Hormuz traffic helped stabilize stocks. Tesla's first-quarter deliveries fell short of expectations, while healthcare stocks declined on tariff concerns.

The Motley Fool•Anders Bylund

Apr 2

Eli Lilly commits over $10 billion to two major strategic initiatives: a $2.75 billion expanded partnership with InSilico Medicine to leverage AI for drug discovery, and a $6.3-7.8 billion acquisition of Centessa Pharmaceuticals to enter the sleep-wake disorders market. These moves aim to modernize R&D processes, diversify revenue beyond its GLP-1 franchise, and support the company's premium valuation.

Investing.com•Jeffrey Neal Johnson

Apr 2

Merck announced its acquisition of Terns Pharmaceutical for $6.7 billion to bolster its cancer treatment pipeline with TERN-701, an oral BCR-ABL1 inhibitor for chronic myeloid leukemia. This marks the third multi-billion-dollar acquisition in a year, reinforcing Merck's M&A strategy. The company has a strong earnings track record, forecasts over $70 billion in commercial opportunity by mid-2030s, maintains a 73% gross margin, and has increased dividends for 14 consecutive years.

Investing.com•Jessica Mitacek

Apr 2

The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.

Benzinga•Tanya Rawat

Apr 2

While Eli Lilly dominates the weight loss drug market with Mounjaro and Zepbound generating $11 billion in the latest quarter, the company's next major growth driver may be artificial intelligence for drug discovery. Lilly is making significant investments in AI through partnerships with Nvidia and Insilico Medicine, aiming to accelerate the drug development process and bring new blockbuster drugs to market across multiple therapeutic areas.

The Motley Fool•Adria Cimino

Apr 2

Eli Lilly's stock surged nearly 4% after the FDA approved Foundayo, its first daily oral weight-loss pill. The drug will compete with Novo Nordisk's Wegovy pill, with pricing starting at $149 monthly. While Wegovy showed higher weight-loss results in trials, Eli Lilly's larger resources and marketing capabilities are expected to drive significant adoption of Foundayo.

The Motley Fool•Eric Volkman

Apr 1

U.S. markets rallied on April 1, 2026, driven by easing Iran war concerns and falling oil prices. The S&P 500 rose 0.72%, Nasdaq climbed 1.16%, and the Dow added 0.48%. Semiconductor stocks surged while energy stocks declined sharply. Nike tumbled 15% on disappointing earnings, while Eli Lilly jumped on FDA approval of its obesity pill. Despite today's gains, the S&P 500 remains down 4% year-to-date.

The Motley Fool•Emma Newbery

Apr 1